Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OlympusTSE:7733 +0.73%84 Debt-to-EBITDA is 1.36 as of Mar. 2026, which is 25% below its 10-year median of 1.82. GuruFocus rates TSE:7733 with a GF Score™ of 84/100 and a GF Value™ of 円2,630.94 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 473 Medical Devices & Instruments companies, Olympus ranks worse than 52.64% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Olympus's Debt-to-EBITDA or its related term are showing as below:
TSE:7733'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.99 Med: 1.82 Max: 2.5
Current: 1.76
During the past 13 years, the highest Debt-to-EBITDA Ratio of Olympus was 2.50. The lowest was 0.99. And the median was 1.82.
TSE:7733's Debt-to-EBITDA is ranked worse than 52.64% of 473
companies
in the Medical Devices & Instruments industry
Industry Median: 1.62
vs TSE:7733: 1.76
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Olympus Debt-to-EBITDA Related Terms
Olympus Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Olympus's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7733 vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Olympus's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Olympus Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Olympus's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Olympus's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Olympus (TSE:7733) has a Debt-to-EBITDA of 1.36 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Olympus. This is 25% below median its historical median of 1.82. Over the past decade, Olympus' Debt-to-EBITDA has ranged from 0.99 to 2.50. According to the industry distribution chart, Olympus ranks #249 out of 473 companies in the Medical Devices & Instruments industry, placing it in the top 52.6%.
Is Olympus' Debt-to-EBITDA too high?
Olympus' current Debt-to-EBITDA of 1.36 is 25% below median its 10-year median of 1.82. Over the past 10 years, this metric has ranged from a low of 0.99 to a high of 2.50. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.62. Olympus' value of 1.36 is 16% below this industry median. Based on the distribution chart, Olympus ranks #249 out of 473 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Olympus has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Olympus' Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Olympus ranks #249 out of 473 companies for Debt-to-EBITDA. This places Olympus in the lower half of its industry. The industry median Debt-to-EBITDA is 1.62. Olympus' value of 1.36 is 16% below this benchmark. Historically, Olympus' own Debt-to-EBITDA has ranged from 0.99 to 2.50 over the past decade. While the company's 10-year median is 1.82 vs. the industry median of 1.62, Olympus has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.62, based on 473 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Olympus's current Debt-to-EBITDA of 1.36 is 16% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Olympus. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Olympus's current Debt-to-EBITDA is 1.36, which is 25% below median its own 10-year median of 1.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Olympus stock overvalued right now?
Based on GuruFocus' analysis, Olympus (TSE:7733) is currently considered Modestly Undervalued. The stock's GF Value™ is 円2,630.94, compared to a current price of 円2,131.50 — trading 19% below its estimated fair value. The current Debt-to-EBITDA is 1.36, which is 25% below median its 10-year median of 1.82 and 16% below the Medical Devices & Instruments industry median of 1.62. Olympus' overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Olympus (TSE:7733), the current Debt-to-EBITDA is 1.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Olympus (TSE:7733) Overvalued in 2026?
Based on GuruFocus' analysis, Olympus stock appears to be undervalued.
The current stock price of 円2,131.50 is trading 19% below its estimated GF Value™ of 円2,630.94.
GuruFocus considers Olympus to be Modestly Undervalued.
Key valuation signals for TSE:7733:
Debt-to-EBITDA: 1.36 (25% below median its 10-year median of 1.82)
GF Value™: 円2,630.94 vs. price of 円2,131.50 (19% below fair value)
Industry Position: 16% below the Medical Devices & Instruments median (#249 of 473)
No single metric tells the full story. See the TSE:7733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Olympus is a medical-device maker with a leading position in the endoscope market and a diversified global revenue stream. Originally founded in 1919 in Japan as a microscope and camera maker, Olympus has gradually pivoted into endoscopic and therapeutic solutions. As of March 2025, more than 60% of its revenue comes from endoscopic solutions. In addition, North America is the biggest revenue contributor by region, accounting for 38% of its total revenue.
84GF Score
Get the complete analysis for TSE:7733
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7733 has been successfully added to your 
